ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

(MedPage Today) — SAN ANTONIO — The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for metastatic hormone receptor-positive/HER2-negative breast cancer…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118963

Author :

Publish date : 2025-12-11 20:07:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

FDA Proposes Allowing New Sunscreen Ingredient

RFK Jr.’s Viral Pull-Ups; Docs Denounce ACIP’s Hep B Vote; ‘Don’t Pee!’

Related Posts

Next DSM Insights; FDA Reviewing Non-Stimulant ADHD Drug; 10M People Microdosing

Viral and Nonviral NICU Infection Rates Diverged During the COVID Pandemic

NIH Data Misused for ‘Race Science’; RFK Jr.’s Autism Committee; NIH Panels at Risk

Study Suggests Some Tap Water May Raise Blood Pressure

Juvenile Localized Scleroderma: MMF Matches Methotrexate

AI model from Google’s DeepMind reads recipe for life in DNA

Next DSM Insights; FDA Reviewing Non-Stimulant ADHD Drug; 10M People Microdosing

Viral and Nonviral NICU Infection Rates Diverged During the COVID Pandemic

NIH Data Misused for ‘Race Science’; RFK Jr.’s Autism Committee; NIH Panels at Risk

Study Suggests Some Tap Water May Raise Blood Pressure

Juvenile Localized Scleroderma: MMF Matches Methotrexate

AI model from Google’s DeepMind reads recipe for life in DNA

The Epstein-Berr virus infects most of us – but why do only some get very ill?

Ancient humans were seafaring far earlier than we realised

Categories

Archives